Biotech company BioMarin Pharmaceutical (NASDAQ: BMRN) met Wall Street’s revenue expectations in Q3 2026, with sales up 32% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $3.85 billion at the midpoint came in 1.8% below analysts’ estimates. Its non-GAAP profit of $0.23 per share was significantly above analysts’ consensus estimates.

Is now the time to buy BMRN? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

BioMarin’s third quarter saw strong underlying business execution, with 32% year-over-year revenue growth driven by expanded demand for metabolic condition therapies such as Galafold and Pombiliti + Opfolda, as well as ongoing momentum in the Voxzogo franchise. Management highlighted that the integration of Amicus exceeded synergy expectations, with Chief Financial Officer Brian Mueller stating, “the cost synergies are ahead of schedule.” However, the market reacted negatively, reflecting concerns arising from order timing disruptions and external headwinds that were evident in the company’s updated guidance.

Looking forward, BioMarin’s revised full-year guidance reflects uncertainties related to large international order timing and increased geopolitical risk in certain regions, not a decline in patient demand. CEO Alexander Hardy emphasized the company’s focus on expanding its clinical pipeline and maintaining commercial growth, while Mueller noted, “the underlying business is performing strongly.” Management’s outlook is shaped by continued international expansion, upcoming regulatory milestones for Voxzogo in hypochondroplasia, and a growing roster of pipeline assets, though they acknowledged that earnings will be impacted by recent acquisitions and timing issues.

Key insights from management’s remarks

Management attributed the quarter’s growth to strong demand across its metabolic and skeletal portfolios, integration of new assets, and progress in expanding its pipeline, while order timing and external disruptions weighed on guidance.

• Metabolic therapies drive growth: Significant contributions from Galafold and Pombiliti + Opfolda led to a 44% increase in metabolic conditions revenue, spurred by successful patient identification and market penetration initiatives.

• Voxzogo global expansion: The number of children treated with Voxzogo increased 17% worldwide, with notable expansion in international markets. Management highlighted recent regulatory approvals in new geographies and ongoing preparations for a hypochondroplasia launch as key growth levers.

• Amicus integration ahead of plan: The acquisition of Amicus accelerated cost synergy realization beyond initial expectations, particularly in commercial and operational functions. Mueller confirmed the transaction will be accretive within nine months post-closing.

• Order timing and external headwinds: A large international customer’s deferred orders and ongoing geopolitical disruptions, especially in the Middle East, led to updated revenue guidance. Management clarified these factors are not tied to patient demand but reflect timing uncertainties.

• Pipeline additions strengthen outlook: Four new assets were added to the pipeline in 2026, including BMN 450 for Fabry disease and BMN 440 for hypophosphatasia. These additions reflect a deliberate strategy to expand the rare disease portfolio and address unmet needs through clinical-stage deals.

Drivers of future performance

Management expects future performance to be shaped by continued product launches, integration of new pipeline assets, and navigating external headwinds impacting order timing.

• Regulatory milestones and launches: Anticipated approval and launch of Voxzogo for hypochondroplasia in the U.S. and Europe are expected to expand the addressable market, with management preparing for rapid access and payer engagement.

• Continued pipeline investment: The addition of assets such as BMN 450 and BMN 440 signals ongoing investment in rare disease R&D, but also increases near-term expenses and impacts non-GAAP earnings due to acquired research and development costs.

• Order timing and geopolitical risks: Management cited ongoing order timing volatility, especially among large international customers, and regional disruptions as key uncertainties for quarterly results, though they expect underlying demand and new launches to support growth into 2027.

Catalysts in upcoming quarters

Looking ahead, the StockStory team will monitor (1) the regulatory progress and launch execution of Voxzogo for hypochondroplasia, (2) realization of Amicus integration synergies and cost control, and (3) the pace of global expansion for metabolic and skeletal therapies, especially in regions affected by order timing volatility and geopolitical disruptions. Pipeline data readouts and progress on new clinical assets will also be critical signposts.

BioMarin Pharmaceutical currently trades at $54.57, down from $57.44 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Our favorite stocks right now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.